Abstract

The liver X receptors (LXRs) are ligand-dependent transcription factors that have been implicated in lipid metabolism and inflammation. LXRs also inhibit the expression of inflammatory genes in macrophages, including inducible nitric oxide synthase (iNOS). Some of these actions are mediated through LXR antagonism of NF-kappaB activity. The potential for LXRs to positively regulate the expression of anti-inflammatory molecules, however, has not been explored. Here we show that the arginase II (ArgII) gene is a direct target for LXR regulation. ArgII catalyzes the conversion of L-arginine into L-ornithine and urea, leading to the synthesis of polyamines. Expression of ArgII is induced by LXR agonists in macrophage cell lines and primary murine macrophages in a receptor-dependent manner. The ArgII promoter contains a functional LXR response elements that mediates promoter induction by LXR/RXR (retinoid X receptor) in transfection assays. Since ArgII and iNOS utilize a common substrate, induction of ArgII expression has the potential to exert anti-inflammatory effects by shifting arginine metabolism toward polyamine synthesis at the expense of NO production. In support of this hypothesis, we demonstrate that forced expression of ArgII mimics the inhibitory effect of LXR activation on macrophage NO production. Furthermore, inhibition of arginase activity partially reverses the inhibitory effect of LXR agonists on NO production. These studies suggest that regulation of ArgII may contribute to the immunomodulatory effects of LXRs.

Highlights

  • These receptors are highly expressed in macrophages and have been shown to mediate lipid and cholesterol homeostasis and to impact the progression of atherosclerosis [3, 4]

  • LPS stimulation promoted arginase II (ArgII) expression in both WT and Previous work has shown that liver X receptors (LXRs) down-regulate the double knockout macrophages

  • These studies suggested that ArgII we analyzed the DNA sequence of the ArgII promoter expression was induced in cells expressing LXRs, whereas for binding sites for LXR/RXR heterodimers

Read more

Summary

EXPERIMENTAL PROCEDURES

Reagents and Plasmids—The specific LXR agonists GW3965 and T0901317 were provided by Tim Willson and Jon Collins (GlaxoSmithKline). Cells were washed with phosphate-buffered saline and cultured in Dulbecco’s modified Eagle’s medium with 1% bovine serum albumin (fatty acid-free, Sigma) before stimulation with LXR ligands and inflammatory products. LXR ligands increased ArgII expression in primary macrophages, the magnitude of this response was smaller than in RAW264.7 cells. Transient and ArgII is regulated by Th2 cytokines (IL-4 and IL-10) and transfections of 293T cells were performed in triplicate using endotoxin (LPS) in macrophages (29 –31). We tested the receptor plasmids (25–50 ng/well), ␤-galactosidase plasmid (25 effect of a combination of LPS and LXR agonist on ArgII ng/well), and empty pCMX plasmids (to a total of 350 ng/well) expression in macrophages obtained from WT and Lxr␣␤Ϫ/Ϫ were transfected overnight. Luciferase activity was induced ArgII protein expression in WT macrophages, whereas normalized to ␤-galactosidase activity This induction was not observed in Lxr␣␤Ϫ/Ϫ macrophages

RESULTS
DISCUSSION
Methods
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call